Lafutidine Ip/bp/usp/ep Cas No: 118288-08-7

Niksan Pharmaceutical is the largest manufacturer and exporter of the Lafutidine among all over the world. Niksan Pharmaceutical is one of biggest the supplier, manufacturer, exporter and distributor of the Lafutidine API and finished formulations in Ankleshwar, Gujarat, India. The products of Niksan Pharmaceutical and Niksan group companies are widely appreciated by the clients and other companies.
Niksan Pharmaceutical is also large exporters of the API and finished pharmaceutical products of Lafutidine in many countries for years. The countries where we exporting are South Korea, Egypt, USA, Japan, Taiwan, UAE, Greece, Indonesia, Uruguay, Thailand, Bolivia, Egypt, Venezuela, Iran, Romania, Ecuador, Hong Kong, Pakistan, Peru, Spain, Turkey, Siberia, Iran, Italy, Vietnam, Germany, Brazil, Philippines, Argentina, Honduras, Columbia, Bulgaria, South Korea, Mexico, Chile, Poland, Hungary, Ireland, Malaysia, Austria, Sweden, Canada, Australia, United kingdom, Ukraine, Russia, France and many more countries.
Niksan Pharmaceutical provides API and finished formulations of Lafutidine in all over Indian states Like Kerala, Gujarat, Haryana, Rajasthan, Madhya Pradesh, Uttar Pradesh, Rajasthan, Karnataka, Meghalaya, Tamilnadu, Goa, Sikkim, Assam, Punjab, Delhi, Bihar, Jammu Kashmir Etc.
Lafutidine belongs to the H2 receptor blocker class of medicine. Lafutidine used in the treatment of stomach and intestinal ulcers by inhibiting the acid secretion from the stomach.

IUPAC NAME: 2-[(furan-2-yl) methanesulfinyl]-N-[(2Z)-4-({4-[(piperidin-1-yl) methyl] pyridin-2-yl} oxy) but-2-en-1-yl] acetamide.
CAS NO: 118288-08-7
FORMULA: C22H29N3O4S
MOLECULAR MASS: 431.55 ga cmol a 1
STORAGE CONDITIONS: Store at room temperature. Keep medicine in dry place. Do not store medicine in bathroom or in humid place. Keep away from children and pets.

HOW TO USE: Not recommended for the age below 18 years. Take medication 2 tome per day. Take medication with or without food.

HOW LAFUTIDINEWORKS: Lafutidine used in the treatment of stomach ulcers and intestinal pain by inhibiting the gastric acid secretion.

PHARMACOKINETICS: Lafutidine absorbed in the small intestine, and binds with the histamine H2 receptors. The half life of Lafutidine is between 1.92+/- 0.94 hours. The 25-30 % of Lafutidine is eliminated by the urination and remaining done by feces.

SIDE EFFECTS OF LAFUTIDINE: Side effects like constipation, rash, nausea and vomiting, sore throat, headache, confusion, insomnia like side effects seen in the patient.

PRECAUTIONS: Do not give medication to children below 12 years. This medicine only used when it is clearly needed.

CDSCO APPROVAL: Lafutidine Tablets-5mg/10mg approved by CDSCO in India in 16.11.09, Lafutidine Tablets-5mg/10mg approved by CDSCO in India in 19.01.10.

FORMULATION AVAILABLE IN MARKET:
Lafutidine 10 mg tablets
Lafutidine 5mg tablets
Lafutidine 10 mg + Domperidone 30mg tablets
Lafutidine 10 mg + Domperidone 10mg tablets
Lafutidine 10 mg + Domperidone 20mg tablets

Note: Product protected by valid patents are not offered for sale in countries where such patents are still valid and its liability is at Buyers Risk

REFERENCES:


https://pubchem.ncbi.nlm.nih.gov


https://www.wikipedia.org/